尿路感染症に対するSigmamycinの応用
スポンサーリンク
概要
- 論文の詳細を見る
The appearance of the resistance in bacteria h a s been a very important problem in the chemotherapy which is performed by many successively discovered new antibiotics . In the experiments in order to solve this problem it is clarified (to be published in detail) that Oleandomycin offered as a new antibiotics by Taito Pfizer Co. has a remarkable good effect and the less side-effects on the tolerant staphylococci while this drug, in vitro, shows no significant inhibitory effect upon the entero-cocci as E. coli etc. Recently a new antibiotics, Sigmamycin, is manufactured by combining Oleandomycin with Tetracycline in Pfizer Co. in order to promote the profitable effects of both Oleandomycine and Tetracycline usually applying to various infection diseases because of its broad antibiotic spectrum. This Sigmamy c in was first brought to us by one of the authors (S. S.) when he was present at an International Meeting of Urology held, a few months ago, at Stockholm, and was afterwards offered by Taito Pfizer Co. The summary of the results of the experiments in which this Sigmamycin was applied to various urogenital infection diseases is described below. 1) Sigmamycin w i t h a broad antibiotic spectrum reaches the effective concentration in blood rapidly after the peroral administration. 2) This shows very intensive a ntagonistic activity on the resistant staphylococci or gonococci, and also the effect upon E. coli can be expected if the care of the using technique and dosages is taken. 3) The continuous us e causes no considerable side effects. 4) The appearance of resistant bacteria is less in f r e quency and very delayed. 5) The application to 16 cases of various urogenital infection resulted i n the efficacy of 81.2%, no effects of 1 and the unknown of 2.
- 泌尿器科紀要刊行会の論文
泌尿器科紀要刊行会 | 論文
- MVAC療法後の転移性尿路上皮癌に対するGemcitabine, Docetaxel, Carboplatin併用化学療法の検討
- Grade 3 Ta-1表在性膀胱癌に対する膀胱温存治療
- 腹腔鏡下に摘出した後腹膜神経線維腫の1例
- 移植腎生検による腎内動脈瘤破裂の1例
- Modified M-VAC療法後に残存腫瘍切除を施行した進行尿路上皮癌患者の治療成績